Showing results (1-10 of 81) with videos related to
Sort By:
Pageof 9
Current Pharmaceutical Design|February 4, 2006
Autoantibody-induced formation of immune complexes in normal human serumRéal Lemieux, Renée BazinImmunology Letters|January 9, 2013
IVIg prevents the in vitro activation of T cells by neutralizing the T cell activatorsLauriane Padet, Renée BazinTransfusion|June 8, 2012
Immunoglobulin G dimers and immune complexes are dispensable for the therapeutic efficacy of intravenous immune globulin in murine immune thrombocytopeniaTony Tremblay, Isabelle Paré, Renée BazinBritish Journal of Haematology|March 8, 2007
Absence of cytokine modulation following therapeutic infusion of intravenous immunoglobulin or anti-red blood cell antibodies in a mouse model of immune thrombocytopenic purpuraEric Aubin, Réal Lemieux, Renée BazinClinical Immunology (Orlando, Fla.)|January 28, 2012
IVIg-mediated inhibition of antigen presentation: predominant role of naturally occurring cationic IgGPatrick Trépanier, Éric Aubin, Renée BazinMolecular Immunology|April 15, 2005
Therapeutic intravenous immunoglobulinsRéal Lemieux, Renée Bazin, Sonia NéronBritish Journal of Haematology|August 24, 2006
Reversal of immune thrombocytopenia in mice by cross-linking human immunoglobulin G with a high-affinity monoclonal antibodyRenée Bazin, Réal Lemieux, Tony TremblayImmunology|October 17, 2013
Intravenous immunoglobulin modulates the expansion and cytotoxicity of CD8+ T cellsPatrick Trépanier, Dominique Chabot, Renée BazinCytokine|December 3, 2014
Involvement of the TNF-α/TGF-β/IDO axis in IVIg-induced immune toleranceLionel Loubaki, Dominique Chabot, Renée BazinClinical Transplantation|April 3, 2015
Use of IVIg to identify potential miRNA targets for allograft rejection and GvHD therapyLauriane Padet, Lionel Loubaki, Renée BazinPageof 9